Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

Mumtaz, Saqib; Goh, Jason; Hirschfield, Gideon; Ferguson, James; Cooper, Sheldon C.

doi:10.1136/flgastro-2016-100711

Cited by 5 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the first review process of all the titles, 11 articles were considered as full text. Of these, eight studies matched the inclusion/exclusion criteria and were finally included 10–17 . All studies were published between 2016–2018.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety of vedolizumab in liver transplant recipients: A systematic review

Spadaccini¹,

Aghemo

Caprioli

et al. 2019

UEG Journal

View full text Add to dashboard Cite

Background The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno-compromised patients. Objective We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Of these, eight studies matched the inclusion/exclusion criteria and were finally included. 10–17 All studies were published between 2016–2018. The study origins were as follows: six studies were from Europe (25 patients), and the remains were from Australia (five patients) and from Argentina (one patient).…”

Section: Resultsmentioning

confidence: 99%

Safety of vedolizumab in liver transplant recipients: A systematic review

Spadaccini¹,

Aghemo

Caprioli

et al. 2019

UEG Journal

View full text Add to dashboard Cite

show abstract

“…The case reports previously discussed highlighted the use of vedolizumab in pre‐, peri‐, and post‐transplant recipients. The risk of infection and adverse effects were similar between patients continuing vedolizumab post‐transplant versus new starts post‐transplant 78–81 …”

Section: Agentsmentioning

confidence: 97%

“…Mumtaz et al. published a case report of a 22‐year‐old patient who underwent LT for PSC IBD 80 . The patient had an uncomplicated post‐transplant course and was discharged home tacrolimus, azathioprine, and tapering prednisolone.…”

Section: Agentsmentioning

confidence: 99%

The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

Szczepanik

Choi

Brady

et al. 2022

Clinical Transplantation

View full text Add to dashboard Cite

Biologics have become the forefront of medicine for management of autoimmune conditions, leading to improved quality of life. Many autoimmune conditions occur in solid organ transplant (SOT) recipients and persist following transplant. However, the use of biologics in this patient population is not well studied, and questions arise related to risk of infection and adjustments to induction and maintenance immunosuppression. Guidelines have been published highlighting management strategies of biologics around the time of elective surgical procedures, but this is not always feasible in urgent situations, especially with deceased donor transplantation. The aim of this review is to summarize the current literature regarding the use of these agents in solid organ transplant recipients, and specifically address induction and maintenance immunosuppression, as well as the need for alternative infective prevention strategies to create This paper represents the opinion of the Immunology/Transplantation Practice and Research Network of the American College of Clinical Pharmacy. It does not necessarily represent an official ACCP commentary, guideline, or statement of policy or position.

show abstract

“…These compounds block a4b7 (vedolizumab, abrilumab), integrin b7 (etrolizumab), and MAdCAM-1 (ontamalimab). Although studies have focused predominantly on the treatment of IBD with these compounds, their potential to block trafficking to the liver suggests they could also be a future treatment option for PSC-IBD and also for inflamed bowel even after liver transplantation (92,93).…”

Section: Inflammatory Bowel Disease and Pscmentioning

confidence: 99%

Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy

et al. 2021

View full text Add to dashboard Cite

The tight relationship between the gut and liver on embryological, anatomical and physiological levels inspired the concept of a gut-liver axis as a central element in the pathogenesis of gut-liver axis diseases. This axis refers to the reciprocal regulation between these two organs causing an integrated system of immune homeostasis or tolerance breakdown guided by the microbiota, the diet, genetic background, and environmental factors. Continuous exposure of gut microbiome, various hormones, drugs and toxins, or metabolites from the diet through the portal vein adapt the liver to maintain its tolerogenic state. This is orchestrated by the combined effort of immune cells network: behaving as a sinusoidal and biliary firewall, along with a regulatory network of immune cells including, regulatory T cells and tolerogenic dendritic cells (DC). In addition, downregulation of costimulatory molecules on hepatic sinusoids, hepatocytes and biliary epithelial cells as well as regulating the bile acids chain also play a part in hepatic immune homeostasis. Recent evidence also demonstrated the link between changes in the gut microbiome and liver resident immune cells in the progression of cirrhosis and the tight correlation among primary sclerosing cholangitis (PSC) and also checkpoint induced liver and gut injury. In this review, we will summarize the most recent evidence of the bidirectional relationship among the gut and the liver and how it contributes to liver disease, focusing mainly on PSC and checkpoint induced hepatitis and colitis. We will also focus on completed therapeutic options and on potential targets for future treatment linking with immunology and describe the future direction of this research, taking advantage of modern technologies.

show abstract

Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

Cited by 5 publications

References 23 publications

Safety of vedolizumab in liver transplant recipients: A systematic review

Safety of vedolizumab in liver transplant recipients: A systematic review

The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy

Contact Info

Product

Resources

About